Provide precise identification of the affected inventory location and product batch. Accuracy is critical for traceability and regulatory compliance.
Facility Name
Facility Type
Distribution Center
Manufacturing Site
Wholesale Depot
Clinical Trial Site
Pharmacy Storage
Third-Party Logistics
Facility Address
Storage Zone Designation
Precise Storage Location Coordinates
Aisle | Rack | Shelf | Bin | ||
|---|---|---|---|---|---|
A | B | C | D | ||
1 | |||||
2 | |||||
3 | |||||
4 | |||||
5 | |||||
6 | |||||
7 | |||||
8 | |||||
9 | |||||
10 |
Product Name
Batch or Lot Number
SKU or Item Code
NDC or Product Code
Quantity on Hand at Time of Breach
Unit of Measure
Vials
Syringes
Cartons
Pallets
Kits
Bottles
Ampoules
Other
Product Receipt Date
Supplier or Manufacturer Name
Purchase Order Number
Operator Name
Operator ID
Shift During Discovery
Day (06:00-14:00)
Evening (14:00-22:00)
Night (22:00-06:00)
Weekend/Holiday
Immediate Supervisor Name
Document the complete temperature excursion profile with precise temporal and thermal data. This section establishes the technical severity of the breach.
Storage Condition Classification
2-8°C Cold Chain
15-25°C Controlled Room Temperature
-20°C Frozen
-80°C Ultra-Low
Liquid Nitrogen Cryogenic
Custom Temperature Range
Specified Temperature Range Minimum (°C)
Specified Temperature Range Maximum (°C)
Temperature Monitoring Device ID
Is the monitoring device currently within its calibration validity period?
Explain calibration status and impact on data reliability:
Breach Detection Method
Automated EMS Alert
Manual Temperature Check
Power Failure Alarm
Equipment Malfunction Alert
Routine Scheduled Inspection
Ad-Hoc Investigation
External Notification
Date and Time of Breach Discovery
Estimated Breach Start Date and Time
Breach End Date and Time (if resolved)
Temperature Readings Log (Record all readings from monitoring device)
Timestamp | Temperature Reading (°C) | Recorded By | Verified by Second Person | ||
|---|---|---|---|---|---|
A | B | C | D | ||
1 | |||||
2 | |||||
3 | |||||
4 | |||||
5 | |||||
6 | |||||
7 | |||||
8 | |||||
9 | |||||
10 |
Maximum Temperature Recorded During Breach (°C)
Minimum Temperature Recorded During Breach (°C)
Variance from Upper Limit (°C)
Variance from Lower Limit (°C)
Ambient Room Temperature at Discovery (°C)
Storage Unit Door Status During Breach
Confirmed Closed
Confirmed Open
Suspected Ajar
Unknown
Not Applicable
Power Status During Breach
Normal Power
Complete Outage
Backup Generator Active
UPS Only
Electrical Fluctuation
Unknown
Equipment Type Involved
Reach-In Refrigerator
Walk-In Cold Room
Ultra-Low Freezer
Cryogenic Tank
Incubator
Climate-Controlled Chamber
Other
Equipment Asset ID
Conduct a thorough assessment of product quality impact based on stability data, visual inspection, and manufacturer guidance. This analysis determines product safety and efficacy implications.
Is stability data or temperature excursion study available for this product?
Upload stability reference document or excursion study report
Explain the absence of stability data and proposed risk mitigation approach:
Has this specific batch experienced any previous temperature excursions?
Previous Excursion Summary
Date | Duration (Hours) | Max Temp (°C) | Previous Disposition | ||
|---|---|---|---|---|---|
A | B | C | D | ||
1 | |||||
2 | |||||
3 | |||||
4 | |||||
5 | |||||
6 | |||||
7 | |||||
8 | |||||
9 | |||||
10 |
Was a visual inspection of affected product performed?
Select all visual abnormalities observed
No visible changes
Discoloration
Precipitation or particulates
Crystallization
Container cracks or damage
Seal compromise
Label deterioration
Package moisture
Other abnormality
Explain why visual inspection was not performed:
Product Category Classification
Vaccine
Monoclonal Antibody
Insulin or Hormone Product
Chemotherapy Agent
Antibiotic
Diagnostic Reagent
Cell or Gene Therapy
Blood Product or Plasma
Small Molecule Pharmaceutical
Compounded Preparation
Other Biologic
Temperature Sensitivity Risk Rating (1=Low, 5=Extremely High)
Exposure Severity Assessment Matrix
Negligible | Minor | Moderate | Severe | Critical | |
|---|---|---|---|---|---|
Duration of breach | |||||
Magnitude of temperature variance | |||||
Product inherent stability | |||||
Number of times limit exceeded | |||||
Confidence in monitoring data |
Has the product manufacturer been notified of this excursion?
Manufacturer Case or Reference Number
Manufacturer Guidance Received
Product is stable - release permitted
Product is unstable - do not release
Further stability testing required
Conditional release with restrictions
Pending investigation - hold product
No guidance received yet
Not contacted
Detailed Product Impact Assessment Summary
Upload supporting technical documentation (stability studies, literature references, risk assessments)
Preliminary Risk Classification
Critical - Product must be destroyed per policy
Major - Conditional release requires QA director approval
Minor - Likely acceptable with enhanced documentation
Unknown - Requires expert panel evaluation
Pending - Awaiting manufacturer or lab results
Document immediate containment actions and develop a clear disposition strategy for the affected inventory. This section ensures product segregation and prevents unintended distribution.
Was immediate physical segregation of affected product completed?
Segregation Completion Timestamp
Justify delay in segregation and interim risk controls implemented:
Quarantine Location Designation
Quarantine Identification Number
Quantity Placed in Quarantine
Quantity Already Distributed or Used Prior to Discovery
Destination of Distributed Product (if any)
Have distributed product recipients been notified?
Provide notification details and recipient responses:
Recommended Disposition Action
Destroy via approved waste management vendor
Return to supplier or manufacturer
Release for restricted or conditional use
Release for normal distribution
Hold pending further investigation
Submit for third-party testing
Other disposition
Approved Destruction Vendor
Return Merchandise Authorization (RMA) Number
Define specific restrictions for conditional release:
Hold Until Date
Testing Laboratory Name
Are physical quarantine labels affixed to all affected stock?
Explain labeling gap and corrective action:
Upload photographs of quarantine labels and segregated product
Cross-Functional Teams Notified
QA Department
Quality Control Laboratory
Regulatory Affairs
Procurement/Supply Chain
Warehouse Management
Clinical Operations
Pharmacovigilance
External Regulatory Authority
Product Supplier
Risk Management
Legal/Compliance
Other Stakeholders
Immediate Corrective Actions Taken
Final authorization by Quality Assurance and Regulatory Affairs leadership. This section confirms formal review, risk acceptance, and regulatory compliance obligations.
QA Reviewer Name
QA Reviewer Title
QA Assessment Date
QA Assessment Time
QA Evaluation Summary and Technical Justification
Does this incident require external regulatory reporting?
Reporting Authority Type
Health Authority
Notified Body
Competent Authority
Ethics Committee
International Regulatory Body
Other Oversight Entity
Regulatory Reference or Case Number
Regulatory Reporting Deadline
Final Approved Disposition
Destroy via approved vendor
Return to supplier
Release for restricted use
Release for normal use
Hold pending investigation
Submit for testing
Other
Rationale if Final Disposition Deviates from Recommendation
Additional Conditions or Restrictions for Release
QA Director Digital Signature
Regulatory Affairs Reviewer Name
Regulatory Affairs Reviewer Title
Regulatory Affairs Assessment Date
Regulatory Affairs Comments and Compliance Assessment
Regulatory Affairs Digital Signature
Final Approval Status
Approved - Proceed with disposition
Approved with Conditions - Comply with restrictions
Rejected - Do not proceed, further review required
Pending - Awaiting additional information
Final Comments and Closure Notes
Form Finalization Date
Form Finalization Time
To configure an element, select it on the form.